Royalty Report: Drugs, cardiac, Pharmaceuticals – Collection: 5058

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drugs
  • cardiac
  • Pharmaceuticals
  • Therapeutic
  • Cancer
  • Delivery
  • Biotechnology
  • Diagnostic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 5058

License Grant
The Licensee entered into an agreement granting it the exclusive right to Licensor’s know-how for the design, development, production, and use of a technology known as pegylation drug formulation and delivery to develop and produce sustained release prostacyclin molecules for the possible treatment of pulmonary hypertension, peripheral vascular disease, stroke, heart disease, cancer, and related diseases worldwide.

IPSCIO Record ID: 4994

License Grant
The Company has an exclusively license for patents and a patent application for the composition and production of the stable prostacyclin analog now known as UT-15 for the treatment of pulmonary hypertension and congestive heart failure and for late-stage peripheral vascular disease.

IPSCIO Record ID: 29073

License Grant
The Licensee entered into an agreement with the University which granted us an exclusive worldwide license, with the right to sublicense, to certain technology covering development, manufacture, use and sale of gene therapy products based on FGF-4 for the treatment of coronary artery disease, peripheral vascular disease and congestive heart failure. FGF-4 shall mean Fibroblast Growth Factor 4, the amino acid sequence.
Field of Use
Field shall mean gene therapy for coronary artery disease, congestive heart failure, and peripheral vascular disease.

IPSCIO Record ID: 3248

License Grant
The parties have entered into a worldwide alliance. The Licensor has Agreements for the codevelopment and cocommercialization of AVAPRO/AVALIDE (irbesartan), an angiotensin II receptor antagonist indicated for the treatment of hypertension and diabetic nephropathy, which is copromoted in certain countries outside the U.S. under the tradename APROVEL/COAPROVEL and comarketed in certain countries outside the U.S. by the Licensor under the tradename KARVEA/KARVEZIDE; and PLAVIX (clopidogrel), a platelet aggregation inhibitor, which is copromoted in certain countries outside the U.S. under the tradename PLAVIX and comarketed in certain countries outside the U.S. by the Company under the tradename ISCOVER.
License Property
Clopidogrel bisulfate is a platelet aggregation inhibitor, which is approved for protection against fatal or non-fatal heart attack or stroke in patients with a history of heart attack, stroke, peripheral arterial disease or acute coronary syndrome.

AVAPRO/AVALIDE is an angiotensin II receptor blocker for the treatment of hypertension.

Field of Use
The rights granted apply to the healthcare industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.